Galera Therapeutics Alpha and Beta Analysis
| GRTXDelisted Stock | USD 2.58 0.19 6.86% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Galera Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Galera Therapeutics over a specified time horizon. Remember, high Galera Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Galera Therapeutics' market risk premium analysis include:
Beta 0.87 | Alpha (0.14) | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Galera |
Galera Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Galera Therapeutics market risk premium is the additional return an investor will receive from holding Galera Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Galera Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Galera Therapeutics' performance over market.| α | -0.14 | β | 0.87 |
Galera Therapeutics Fundamentals Vs Peers
Comparing Galera Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Galera Therapeutics' direct or indirect competition across all of the common fundamentals between Galera Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Galera Therapeutics or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Galera Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Galera Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Galera Therapeutics to competition |
| Fundamentals | Galera Therapeutics | Peer Average |
| Return On Equity | -10.63 | -0.31 |
| Return On Asset | -0.59 | -0.14 |
| Current Valuation | 146.68 M | 16.62 B |
| Shares Outstanding | 54.39 M | 571.82 M |
| Shares Owned By Insiders | 36.15 % | 10.09 % |
| Shares Owned By Institutions | 18.95 % | 39.21 % |
| Number Of Shares Shorted | 2.12 M | 4.71 M |
Galera Therapeutics Opportunities
Galera Therapeutics Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
About Galera Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Galera or other pink sheets. Alpha measures the amount that position in Galera Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Galera Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Galera Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Galera Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Galera Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Galera Therapeutics. Please utilize our Beneish M Score to check the likelihood of Galera Therapeutics' management manipulating its earnings.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Galera Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Galera Pink Sheet
If you are still planning to invest in Galera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Galera Therapeutics' history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |